Achmea Investment Management B.V. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,400 shares of the medical research company’s stock after selling 2,013 shares during the period. Achmea Investment Management B.V.’s holdings in Thermo Fisher Scientific were worth $4,977,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Xact Kapitalforvaltning AB lifted its position in shares of Thermo Fisher Scientific by 0.5% during the second quarter. Xact Kapitalforvaltning AB now owns 90,066 shares of the medical research company’s stock worth $18,656,000 after purchasing an additional 405 shares in the last quarter. Gateway Investment Advisers LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $4,147,000. BLB&B Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $311,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $284,000. Finally, Lodestar Investment Counsel LLC IL increased its position in shares of Thermo Fisher Scientific by 1.7% during the second quarter. Lodestar Investment Counsel LLC IL now owns 76,231 shares of the medical research company’s stock worth $15,791,000 after acquiring an additional 1,250 shares in the last quarter. 86.98% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have commented on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $269.00 price target for the company in a research note on Wednesday, November 28th. Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a research report on Thursday, October 25th. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, October 25th. Citigroup increased their price objective on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, October 10th. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the company an “overweight” rating in a research report on Monday, September 24th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $263.45.
TMO stock traded up $2.43 during mid-day trading on Monday, hitting $251.98. The stock had a trading volume of 2,188,700 shares, compared to its average volume of 1,463,805. Thermo Fisher Scientific Inc. has a 52 week low of $181.51 and a 52 week high of $253.91. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. The firm has a market cap of $100.46 billion, a P/E ratio of 26.55, a P/E/G ratio of 1.81 and a beta of 1.09.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.07. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The company had revenue of $5.92 billion for the quarter, compared to the consensus estimate of $5.70 billion. During the same period last year, the company posted $2.31 EPS. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. Equities analysts predict that Thermo Fisher Scientific Inc. will post 11.04 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be given a dividend of $0.17 per share. The ex-dividend date is Friday, December 14th. This represents a $0.68 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Friday, September 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 2.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: What is the Federal Reserve?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.